Effects of fumarate on renal vascular reactivity and the modulation of blood pressure in normotensive rats: Possible contribution of the nitric oxide synthase-nitric oxide system

Introduction: Fumarate, the tricarboxylic acid (TCA) cycle intermediary, has been linked to nitric oxide (NO) production. NO plays a prominent role in the physiological regulation of blood pressure and renal hemodynamics. This study is aimed to investigate any contribution of fumarate...

Full description

Saved in:
Bibliographic Details
Main Authors: Osaze Edosuyi (Author), Myung Choi (Author), Ighodaro Igbe (Author), Adebayo Oyekan (Author)
Format: Book
Published: Belgorod National Research University, 2022-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_432924d166ea4e02a08e7f9af7b1c6b9
042 |a dc 
100 1 0 |a Osaze Edosuyi  |e author 
700 1 0 |a Myung Choi  |e author 
700 1 0 |a Ighodaro Igbe  |e author 
700 1 0 |a Adebayo Oyekan  |e author 
245 0 0 |a Effects of fumarate on renal vascular reactivity and the modulation of blood pressure in normotensive rats: Possible contribution of the nitric oxide synthase-nitric oxide system 
260 |b Belgorod National Research University,   |c 2022-08-01T00:00:00Z. 
500 |a 10.3897/rrpharmacology.8.79765 
500 |a 2658-381X 
520 |a Introduction: Fumarate, the tricarboxylic acid (TCA) cycle intermediary, has been linked to nitric oxide (NO) production. NO plays a prominent role in the physiological regulation of blood pressure and renal hemodynamics. This study is aimed to investigate any contribution of fumarate to blood pressure and renal hemodynamics in normotensive rats with a possible link to the nitrergic system. Materials and methods: Fumarate (1, 3 and 10 µmol) was injected into isolated perfused kidneys, pre-constricted with epinephrine (30 µM). The fumarase inhibitor, pyromellitic acid (PMA) (1, 3 and 10 µM), was used to perfuse the isolated kidney and perfusate was collected for nitric oxide and fumarate assays. An acute blood pressure study involved the injection of bolus doses of fumarate (0.1, 0.3 and 1 µg/kg, iv) or PMA (1, 3 and 10 µg/kg, iv) to normotensive rats in the presence of N(ω)-nitro-L-arginine methyl ester (L-NAME) (10 mg/kg, iv) or PMA (1, 3 and 10 µg/kg). Results and discussion: Fumarate reduced perfusion pressure and elicited a peak reduction at the highest dose. Perfusing the kidney with PMA caused a paradoxical increase in perfusion pressure (70%, p<0.05), compared to baseline. Bolus doses of fumarate reduced blood pressure (-29.3±6.2 mmHg, p<0.05), cortical blood flow (CBF) and increased medullary blood flow (MBF). L-NAME did not abolish the vasodilatory effect of fumarate, but reduced the magnitude of response (50%, p<0.05). PMA did not significantly affect the vasodilatory effect of fumarate (p>0.05). Conclusion: These data suggest that fumarate exerts a vasodilatory effect on renal and systemic hemodynamics that may partly involve the nitric oxide signaling. Graphical abstract: 
546 |a EN 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Research Results in Pharmacology, Vol 8, Iss 3, Pp 31-40 (2022) 
787 0 |n https://rrpharmacology.ru/article/79765/download/pdf/ 
787 0 |n https://rrpharmacology.ru/article/79765/download/xml/ 
787 0 |n https://rrpharmacology.ru/article/79765/ 
787 0 |n https://doaj.org/toc/2658-381X 
856 4 1 |u https://doaj.org/article/432924d166ea4e02a08e7f9af7b1c6b9  |z Connect to this object online.